Carbasalate veterinary grade API is supplied as a calcium acetylsalicylate urea complex, with the CAS registry designation 5749-67-7 commonly used in commercial quality documentation. The substance is classified as a non-sterile active pharmaceutical ingredient for veterinary use, intended for further processing into tablets, capsules, powders, granules, premixes, injectable solutions, and drinking-water concentrates. The presence of the urea complex confers aqueous solubility that is absent in acetylsalicylic acid and removes the need for alkaline salt formation when a liquid dose is prepared. Manufacturer model designations generally distinguish a standard crystalline grade from a milled or low-dust grade; the milled grade is specified when dry blending into premixes and powders, while the crystalline grade is used in wet granulation and direct compression development.

The release specification for carbasalate calcium veterinary grade is not harmonized in all pharmacopoeias; therefore, dosage-form manufacturers commonly qualify the API against a buyer specification that incorporates general pharmacopoeial methods and VICH GL1/VICH GL2 validation principles. Table 1 lists an illustrative profile for an oral-grade powder. Injectable-grade material carries additional endotoxin and bioburden requirements.

Table 1. Illustrative release specification for oral-grade carbasalate calcium.

The powder is hygroscopic due to the urea complex. Storage in sealed polyethylene-lined aluminium pouches is specified at ≤ 25 °C and ≤ 60% relative humidity. Unprotected exposure to high-humidity air above 60% RH can produce agglomerates and reduce powder flow; however, chemical degradation measured by HPLC assay remains limited over short excursions when the product is re-dried under validated conditions. Prolonged exposure above 60 °C should be avoided because hydrolysis of the acetyl group and dissociation of the urea complex can shift the impurity profile. In aqueous solution, the rate of acetylsalicylate hydrolysis is pH-dependent and increases with temperature. Published stability data for carbasalate calcium in all veterinary dosage forms is limited; therefore, the in-use period for stock solutions must be established by stability-indicating HPLC under worst-case storage conditions.

What Analytical Boundaries Separate Carbasalate from Acetylsalicylic Acid and Sodium Salicylate?

Carbasalate calcium is not a simple salt of acetylsalicylic acid. It contains calcium and urea in a complex that alters the aqueous solubility and the salicylate equivalent per gram of active substance. Under general pharmacopoeial solubility categories, carbasalate calcium is freely soluble in water, whereas acetylsalicylic acid is practically insoluble. Sodium salicylate is also freely soluble, but it contributes a sodium load and produces a more alkaline solution. The difference in active-moiety content requires an assay correction when replacing acetylsalicylic acid in a formulation; the conversion is not performed on a 1:1 weight basis.

Table 2 summarizes the formulation-relevant differences. The data are drawn from general pharmacopoeial solubility definitions and standard pharmaceutical formulation observations, not from species-specific bioequivalence studies.

Table 2. Comparative formulation-relevant properties of salicylate APIs.

In solid oral dosage forms, the water-soluble complex provides faster dissolution than acetylsalicylic acid under neutral dissolution conditions, but the in vivo release of salicylate depends on the hydrolysis rate in the gastrointestinal fluid. Dissolution testing for carbasalate-containing tablets should use a stability-indicating HPLC method rather than a simple UV absorbance method, because the parent complex and free salicylic acid may have overlapping ultraviolet absorption profiles. Method transfer between laboratories requires peak purity verification according to ICH Q2(R1) or VICH GL2.

Solid oral dosage processing is governed by particle-size control, not by simple mixing time.

For tablet and capsule manufacture, the API is typically dry-blended with microcrystalline cellulose and lactose monohydrate in a bin blender. Direct compression is evaluated only when flowability data from the manufacturer COA demonstrate acceptable powder rheology; if the Hausner ratio exceeds 1.35 or the angle of repose exceeds 40°, the blend is granulated. Wet granulation is carried out in a high-shear granulator using purified water; the wet mass is passed through a 1.0 mm screen and dried in a fluid-bed dryer. The drying endpoint is confirmed by loss on drying ≤ 1.5% in the granulate; overdrying below 0.5% can reduce compactibility by collapsing the porous structure needed for interparticulate bonding. Compression is performed on a rotary tablet press. Disintegration is tested using Ph. Eur. 2.9.1 or USP <701>; the acceptance value is set during development because no universal monograph applies to all carbasalate-containing tablets. For capsules, an auger or tamping-pin filler is used, and suite relative humidity is maintained below 50% to reduce sticking caused by the hygroscopic urea component.

Water-soluble powders and premixes require a low-dust, free-flowing form. The milled API is mixed with a carrier such as dextrose monohydrate or lactose in a ribbon blender or double-cone blender, then screened through a 500 µm sieve. Homogeneity of the medicated premix is checked by sampling the blender discharge and by HPLC assay; acceptance limits are normally expressed as a percentage of label claim, commonly 90%–110% for individual samples and 95%–105% for the mean. In feed-mill premix operations, static charge and hygroscopicity are controlled because the urea-containing powder can cake when relative humidity exceeds 60%. Granulation is used for low-dust formulations and where dust containment is critical.

Injectable Formulations and the Limits of Terminal Processing

Injectable-grade carbasalate calcium differs from oral-premix material in endotoxin control, bioburden, and particulate requirements. The API is soluble in water, but aqueous solutions undergo pH-dependent hydrolysis; therefore, injectable formulations are often prepared as non-aqueous solutions, co-solvent systems, or solutions with a buffered pH. Terminal sterilization by autoclaving is not automatically applicable because heat accelerates hydrolysis of the acetyl group. Sterile filtration followed by aseptic filling is the practical route when the solution is sufficiently stable. For intramuscular or intravenous administration, the solution pH is maintained within a range that minimizes injection-site irritation while preserving the acetylsalicylate moiety; this range is established by forced-degradation studies using stability-indicating HPLC.

Endotoxin acceptance for injectable-grade material is derived from the maximum intended dose and the target species. Testing is conducted according to Ph. Eur. 2.6.14 or USP <85>. Particulate matter is evaluated by Ph. Eur. 2.9.19 or USP <788>. The API manufacturer should provide bioburden and endotoxin data when the material is designated for parenteral use; oral-grade material may not be acceptable for injectable processing without additional purification and validation.

If the target species is poultry or swine, what changes in drinking-water medication?

When carbasalate calcium is administered through the drinking water of broilers, turkeys, or swine, the high aqueous solubility of the urea complex permits preparation of a concentrated stock solution. The stock solution is then metered into the drinking-water distribution line through a proportioner or dosing pump. The pH of the medicated water is not strongly depressed, so the formulation is less corrosive to galvanized equipment than an acidic acetylsalicylic acid suspension. However, the stock solution has a finite in-use stability due to hydrolysis; the permitted in-use period must be established by stability-indicating HPLC under worst-case storage conditions. Water hardness and mineral content can affect the ionic strength of the diluted solution; the dosage-form manufacturer should provide compatibility data for typical hard-water conditions. Dosing is based on species-specific pharmacokinetic parameters and current regulatory withdrawal-period guidance; no universal dose can be assigned without reference to the target species and clinical indication.

Carbasalate calcium is not interchangeable with acetylsalicylic acid or sodium salicylate on a weight basis. The calcium and urea components change the salicylate equivalent per gram, so a formulation change requires molar correction and dissolution comparison in the target dosage form. In tablet formulations, high levels of magnesium stearate can delay dissolution; the lubricant level is optimized using Ph. Eur. 2.9.3 or USP <711>. The API should not be dry-blended with hygroscopic choline chloride or with mineral premixes containing free moisture, because caking and hydrolysis may occur. Avoid contact with strong acids, strong bases, oxidizing agents, and heavy-metal ions. In aqueous solution, avoid cationic polymers unless compatibility is confirmed by HPLC assay and pH drift studies. As with other salicylates, use in cats is contraindicated because of slow glucuronidation and prolonged elimination; this is a species-specific pharmacokinetic limitation, not a formulation incompatibility.

Storage of the unmixed API in sealed polyethylene-lined aluminium pouches is specified at ≤ 25 °C and ≤ 60% relative humidity. Under these conditions, the release specification is maintained for the assigned retest period; re-evaluation should follow VICH GL3(R) principles. The material should be re-dried only after compatibility of the drying temperature with the urea complex has been confirmed by HPLC assay and related-substance testing.